Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)

JP2023549229A5Active Publication Date: 2024-11-21BICYCLETX LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528449
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-29
Filing Date
2021-11-12
Publication Date
2024-11-21
Estimated Expiration
2041-11-12

Smart Images

  • Figure 2022101633000001
    Figure 2022101633000001
  • Figure 2022101633000002
    Figure 2022101633000002
  • Figure 2022101633000003
    Figure 2022101633000003
Patent Text Reader

Abstract

The present invention relates to polypeptides covalently attached to a molecular scaffold such that two or more peptide loops are interposed between the attachment points to the scaffold. In particular, the present invention describes peptides that bind to TfR1. The present invention also relates to multimeric binding complexes comprising at least two of the bicyclic peptide ligands. The present invention also includes pharmaceutical compositions comprising the peptide ligands and multimeric binding complexes, as well as the use of the peptide ligands, multimeric binding complexes, and pharmaceutical compositions in the prevention, suppression, or treatment of diseases or disorders through the delivery of therapeutic agents mediated by TfR1.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A peptide ligand specific for transferrin receptor 1 (TfR1), or a pharma- ceutical acceptable salt thereof, comprising a polypeptide comprising at least three reactive groups separated by at least two loop sequences and a molecular scaffold that forms covalent bonds with the reactive groups of the polypeptide, such that at least two polypeptide loops are formed on the molecular scaffold.

2. 2. The peptide ligand or a pharma- ceutically acceptable salt thereof according to claim 1, wherein the reactive group comprises a cysteine ​​residue.

3. 3. The peptide ligand or a medicamentously acceptable salt thereof according to claim 1 or 2, wherein the peptide ligand inhibits binding between transferrin and TfR1.

4. 4. The peptide ligand or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 3, wherein the loop sequence comprises 2, 3, 6, 8, or 9 amino acids.

5. 5. The peptide ligand or a pharma- ceutically acceptable salt thereof according to claim 4, wherein the loop sequence comprises three cysteine ​​residues separated by two loop sequences, the first of which consists of two amino acids and the second of which consists of nine amino acids.

6. 5. The peptide ligand or a pharma- ceutically acceptable salt thereof according to claim 4, wherein the loop sequence comprises three cysteine ​​residues separated by two loop sequences, both of which consist of six amino acids.

7. 5. The peptide ligand or a pharma- ceutically acceptable salt thereof according to claim 4, wherein the loop sequence comprises three cysteine ​​residues separated by two loop sequences, the first of which consists of three amino acids and the second of which consists of eight amino acids.

8. The peptide ligand is 【Chemistry 1】 (Here, C i , C ii , and C iii represent the first, second, and third cysteine ​​residues, respectively. or a modified derivative thereof, or a pharma- ceutically acceptable salt thereof, for example, where the molecular scaffold is 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)triplo-2-en-1-one (TATA) and the peptide ligand comprises an N- and / or C-terminal addition; and A-(SEQ ID NO:1)-A (referred to herein as BCY12455); A-(SEQ ID NO:1)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY12652); A-(SEQ ID NO:2)-A (referred to herein as BCY12452); A-(SEQ ID NO:2)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY12650); A-(SEQ ID NO:3)-A (referred to herein as BCY12454); and A-(SEQ ID NO:3)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY12651) or a modified derivative thereof, or a pharma- ceutical acceptable salt thereof. (where Sar stands for sarcosine and Fl stands for fluorescein) 5. The peptide ligand according to claim 4, or a pharma- ceutical acceptable salt thereof, selected from:

9. 3. The peptide ligand or a medicamentously acceptable salt thereof according to claim 1 or 2, wherein the peptide ligand does not inhibit the binding of transferrin to TfR1.

10. 10. The peptide ligand or a pharma- ceutically acceptable salt thereof according to claim 9, wherein the loop sequence comprises 3 or 7 amino acids.

11. 11. The peptide ligand or a pharma- ceutically acceptable salt thereof according to claim 10, wherein the loop sequence comprises three cysteine ​​residues separated by two loop sequences, the first of which consists of seven amino acids and the second of which consists of three amino acids.

12. The peptide ligand is 【Chemistry 2】 【change】 【change】 (wherein Abu represents aminobutyric acid, Aib represents aminoisobutyric acid, Aze represents azetidine, B-MeIle represents β-methylisoleucine, C5g represents cyclopentylglycine, Cba represents β-cyclobutylalanine, Cbg represents cyclobutylglycine, Chg represents cyclohexylglycine, Cpg represents cyclopropylglycine, EPA represents 2-amino-3-ethyl-pentanoic acid, HyP represents trans-4-hydroxy-L-proline, [K(N 3 )] represents 6-azidolysine, 1Nal represents 1-naphthylalanine, 2Nal represents 2-naphthylalanine, 4Pal represents 4-pyridylalanine, tBuAla represents t-butyl-alanine, tBuGly represents t-butyl-glycine, 3tBuTyr represents 3-t-butyl-tyrosine, and C i , C ii , and C iii represent the first, second, and third cysteine ​​residues, respectively. or a modified derivative thereof, or a pharma- ceutically acceptable salt thereof, For example, wherein the molecular scaffold is 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)tris(2-bromoethanone) (TATB) and the peptide ligand or a pharma- ceutically acceptable salt thereof comprises an N- and / or C-terminal addition; and A-(SEQ ID NO:4)-A (referred to herein as BCY13983); A-(SEQ ID NO:4)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY14474); A-(SEQ ID NO:5)-A (referred to herein as BCY13986); A-(SEQ ID NO:5)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY14475); A-(SEQ ID NO:6)-A (referred to herein as BCY15466); Ac-(SEQ ID NO:6) (referred to herein as BCY15889); A-(SEQ ID NO:7)-A (referred to herein as BCY15467); Ac-(SEQ ID NO:7) (referred to herein as BCY15890); A-(SEQ ID NO:8)-A (referred to herein as BCY13989); A-(SEQ ID NO:8)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY14476); A-(SEQ ID NO:9)-A (referred to herein as BCY15468); A-(SEQ ID NO:9)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15768); (SEQ ID NO: 9) - [Sar 6 ]-[K-Fl] (referred to herein as BCY15934); Ac-(SEQ ID NO:9)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15937); Ac-(SEQ ID NO:9)-[Sar 6 ]-[K-Fl] (referred to herein as BCY15938); [Fl]G[Sar 5 ]-A-(SEQ ID NO:9)-A (referred to herein as BCY15940); N[1Nal]N-(SEQ ID NO:9) (referred to herein as BCY18030); Ac-(SEQ ID NO:9)-E[Pip]W (referred to herein as BCY18039); Ac-(SEQ ID NO:9)-EPW (referred to herein as BCY17994); NWN-(SEQ ID NO:9) (referred to herein as BCY18029); NWN-(SEQ ID NO:9)-A (referred to herein as BCY17109); Ac-(SEQ ID NO:9)-E[Aze]W (referred to herein as BCY18037); Ac-NWN-(SEQ ID NO:9) (referred to herein as BCY17992); Ac-(SEQ ID NO:9)-E[dP]W (referred to herein as BCY18038); Ac-N[1Nal]N-(SEQ ID NO:9) (referred to herein as BCY18034); N[dW]N-(SEQ ID NO:9) (referred to herein as BCY18031); Ac-N[dW]N-(SEQ ID NO:9) (referred to herein as BCY18035); HWM-(SEQ ID NO:9)-A (referred to herein as BCY17110); A-(SEQ ID NO:9)-PHP (referred to herein as BCY17115); A-(SEQ ID NO:9)-EPW (referred to herein as BCY17114); NEV-(SEQ ID NO:9)-A (referred to herein as BCY17112); A-(SEQ ID NO:9)-PIVH (referred to herein as BCY17120); Ac-(SEQ ID NO:9) (referred to herein as BCY15891); HTS-(SEQ ID NO:9)-A (referred to herein as BCY17111); Ac-N[NMeTrp]N- (SEQ ID NO: 9) (referred to herein as BCY18036); N[NMeTrp]N- (SEQ ID NO: 9) (referred to herein as BCY18032); Ac-A-(SEQ ID NO:9)-A (referred to herein as BCY15939); A-(SEQ ID NO:9)-EHQE (referred to herein as BCY17119); ESF-(SEQ ID NO:9)-A (referred to herein as BCY17113); NWN-(SEQ ID NO:9)-[K(N 3 )] (referred to herein as BCY17870); Ac-NWN-(SEQ ID NO: 9)-[K(N 3 )] (referred to herein as BCY17871); [AzPro]-NWN-(SEQ ID NO:9) (referred to herein as BCY17872); Ac-(SEQ ID NO:9)-EPW-[K(N 3 )] (referred to herein as BCY17873); [AzPro]-(SEQ ID NO:9)-EPW (referred to herein as BCY17874); Ac-(SEQ ID NO:9)-[K(N 3 )] (referred to herein as BCY17868); [AzPro]-(SEQ ID NO:9) (referred to herein as BCY17869); Ac-N[dY]N-(SEQ ID NO: 9)-[K(N 3 )] (referred to herein as BCY17882); Ac-(SEQ ID NO:9)-E-[dP]-W-[K(N 3 )] (referred to herein as BCY17890); Ac-(SEQ ID NO:9)-E-[Aze]-W-[K(N 3 )] (referred to herein as BCY17892); Ac-(SEQ ID NO:9)-E-[Pip]-W-[K(N 3 )] (referred to herein as BCY17894); Ac-(SEQ ID NO:9)-[K(N 3 ) (PYA-maleimide)] (referred to herein as BCY17906); Ac-(SEQ ID NO:9)-EPW-[Peg 10 ]-[K(N 3 )] (referred to herein as BCY19405); Ac-(SEQ ID NO:9)-EPW-[Peg 24 ]-[K(N 3 )] (referred to herein as BCY19406); Ac-(SEQ ID NO: 9)-EPWGGSGGS-[K(N 3 )] (referred to herein as BCY19407); A-(SEQ ID NO:10)-A (referred to herein as BCY15469); Ac-(SEQ ID NO:10) (referred to herein as BCY15892); A-(SEQ ID NO:11)-A (referred to herein as BCY15470); Ac-(SEQ ID NO:11) (referred to herein as BCY15893); A-(SEQ ID NO:12)-A (referred to herein as BCY15471); Ac-(SEQ ID NO:12) (referred to herein as BCY15894); Ac-(SEQ ID NO:13) (referred to herein as BCY17991); Ac-(SEQ ID NO:13)-EPW (referred to herein as BCY17995); Ac-NWN-(SEQ ID NO:13) (referred to herein as BCY17993); NWN-(SEQ ID NO:13) (referred to herein as BCY18033); A-(SEQ ID NO:13)-A (referred to herein as BCY16754); Ac-(SEQ ID NO:13)-[K(N 3 )] (referred to herein as BCY17896); Ac-NWN-(SEQ ID NO:13)-[K(N 3 )] (referred to herein as BCY17899); Ac-(SEQ ID NO: 13)-EPW-[K(N 3 )] (referred to herein as BCY17901); Ac-(SEQ ID NO:14) (referred to herein as BCY17990); Ac-(SEQ ID NO:14)-[K(N 3 )] (referred to herein as BCY17875); [AzPro]-(SEQ ID NO:14) (referred to herein as BCY17876); Ac-(SEQ ID NO:15) (referred to herein as BCY17989); A-(SEQ ID NO:15)-A (referred to herein as BCY16047); Ac-(SEQ ID NO:15)-[K(N 3 )] (referred to herein as BCY17877); [AzPro]-(SEQ ID NO:15) (referred to herein as BCY17878); A-(SEQ ID NO:16)-A (referred to herein as BCY16962); TYMN-(SEQ ID NO:17)-A (referred to herein as BCY17117); A-(SEQ ID NO:17)-A (referred to herein as BCY16048); A-(SEQ ID NO:18)-A (referred to herein as BCY16963); Ac-(SEQ ID NO:19) (referred to herein as BCY17987); A-(SEQ ID NO:20)-A (referred to herein as BCY16753); A-(SEQ ID NO:21)-A (referred to herein as BCY16046); A-(SEQ ID NO:22)-A (referred to herein as BCY16964); A-(SEQ ID NO:23)-A (referred to herein as BCY16965); Ac-(SEQ ID NO:24) (referred to herein as BCY17986); A-(SEQ ID NO:25)-A (referred to herein as BCY16550); A-(SEQ ID NO:26)-A (referred to herein as BCY16966); A-(SEQ ID NO:27)-A (referred to herein as BCY16051); IDSN-(SEQ ID NO:28)-A (referred to herein as BCY17118); WGKS-(SEQ ID NO:29)-A (referred to herein as BCY17116); A-(SEQ ID NO:30)-A (referred to herein as BCY16053); A-(SEQ ID NO:31)-A (referred to herein as BCY16557); A-(SEQ ID NO:32)-A (referred to herein as BCY16035); A-(SEQ ID NO:33)-A (referred to herein as BCY16043); A-(SEQ ID NO:34)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15769); A-(SEQ ID NO:35)-A (referred to herein as BCY15648); A-(SEQ ID NO:36)-A (referred to herein as BCY16031); A-(SEQ ID NO:37)-A (referred to herein as BCY16079); A-(SEQ ID NO:38)-A (referred to herein as BCY16036); A-(SEQ ID NO:39)-A (referred to herein as BCY16029); A-(SEQ ID NO:40)-A (referred to herein as BCY16089); A-(SEQ ID NO:41)-A (referred to herein as BCY16088); A-(SEQ ID NO:42)-A (referred to herein as BCY16052); A-(SEQ ID NO:43)-A (referred to herein as BCY16033); A-(SEQ ID NO:44)-A (referred to herein as BCY16039); Ac-(SEQ ID NO:44) (referred to herein as BCY17988); Ac-(SEQ ID NO:44)-[K(N 3 )] (referred to herein as BCY17879); [AzPro]-(SEQ ID NO:44) (referred to herein as BCY17880); A-(SEQ ID NO:45)-A (referred to herein as BCY16038); A-(SEQ ID NO:46)-A (referred to herein as BCY16050); A-(SEQ ID NO:47)-A (referred to herein as BCY16034); A-(SEQ ID NO:48)-A (referred to herein as BCY16032); A-(SEQ ID NO:49)-A (referred to herein as BCY16049); A-(SEQ ID NO:50)-A (referred to herein as BCY16558); A-(SEQ ID NO:51)-A (referred to herein as BCY16041); A-(SEQ ID NO:52)-A (referred to herein as BCY16042); A-(SEQ ID NO:53)-A (referred to herein as BCY16045); A-(SEQ ID NO:54)-A (referred to herein as BCY16037); A-(SEQ ID NO:55)-A (referred to herein as BCY16044); A-(SEQ ID NO:56)-A (referred to herein as BCY16040); A-(SEQ ID NO:57)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15771); A-(SEQ ID NO:58)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15772); A-(SEQ ID NO:59)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15773); A-(SEQ ID NO:60)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15774); A-(SEQ ID NO:61)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15775); A-(SEQ ID NO:62)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15776); A-(SEQ ID NO:63)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15777); A-(SEQ ID NO:64)-A-[Sar 6 ]-[K-Fl] (referred to herein as BCY15770); Ac-(SEQ ID NO:65) (referred to herein as BCY17903); Ac-(SEQ ID NO:66) (referred to herein as BCY17904); and Ac-(SEQ ID NO:67) (referred to herein as BCY17905); or a modified derivative thereof, or a pharma- ceutical acceptable salt thereof. (wherein AzPro represents azidopropyl, Aze represents azetidine, 1Nal represents 1-naphthylalanine, NMeTrp represents N-methyl-tryptophan, [K(N 3 )] represents 6-azidolysine, Peg represents polyethylene glycol, Pip represents pipecolic acid, Sar represents sarcosine, Fl represents fluorescein, [K(N 3 ) (PYA-maleimide)] has the following structure: 【Chemistry 3】 represents a modified lysine having the formula or wherein the molecular scaffold is 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)triplop-2-en-1-one (TATA) and the peptide ligand comprises an N- and / or C-terminal addition; and Ac- (SEQ ID NO: 13) (referred to herein as BCY20546) or a modified derivative thereof, or a pharma- ceutical acceptable salt thereof.

12. The peptide ligand according to any one of claims 9 to 11, or a pharma- ceutical acceptable salt thereof, wherein:

13. 13. The peptide ligand or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 12, wherein the pharma- ceutically acceptable salt is selected from a free acid or a sodium, potassium, calcium, or ammonium salt.

14. A multimeric binding complex comprising at least two of the peptide ligands or pharma- ceutically acceptable salts thereof according to any one of claims 1 to 13.

15. Compounds of formula (I): 【Chemistry 4】 (Wherein, CHM represents the central hinge portion; Bicyclic represents a bicyclic peptide ligand according to any one of claims 1 to 13 or a pharma- ceutically acceptable salt thereof; and m represents an integer selected from 2 to 10, for example, 2, 3, or 4.

15. The multimeric binding complex of claim 14, comprising:

16. m represents 2 and CHM represents formula (A): 【Chemistry 5】 For example, BCY19409 The multimeric binding complex of claim 15, wherein the motif is

17. 17. A pharmaceutical composition comprising a peptide ligand according to any one of claims 1 to 13 or a pharma- ceutically acceptable salt thereof or a multimeric binding complex according to any one of claims 14 to 16, in combination with one or more pharma- ceutically acceptable excipients.

18. A pharmaceutical for preventing, suppressing or treating a disease or disorder by delivery of a therapeutic agent mediated by TfR1, comprising as an active ingredient a peptide ligand or a pharma- ceutical acceptable salt thereof according to any one of claims 1 to 13, or a multimeric binding complex according to any one of claims 14 to 16, or a pharmaceutical composition according to claim 17.

19. A tissue delivery complex comprising a peptide ligand according to any one of claims 1 to 13 or a pharma- ceutically acceptable salt thereof, or a multimeric binding complex according to any one of claims 14 to 16, bound to Tfr1, in combination with a payload, e.g., an oligonucleotide, in particular an siRNA.

20. 20. The tissue delivery complex of claim 19, which is a muscle tissue delivery complex.

21. 21. A medicament for treating a musculoskeletal disorder, comprising the tissue delivery complex of claim 19 or claim 20 as an active ingredient.

22. Use of a peptide ligand or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 13, a multimeric binding complex according to any one of claims 14 to 16, or a pharmaceutical composition according to claim 17, in the manufacture of a medicament for treating a disease or disorder by delivery of a therapeutic agent mediated by TfR1.

23. 21. Use of the tissue delivery complex of claim 19 or 20 in the manufacture of a medicament for treating a musculoskeletal disorder.